Healthcare provider profile · identity verified

Mark E Obrien, MD

Allopathic & Osteopathic Physicians|Internal Medicine · BENTON HARBOR, MI · NPI 1841221348

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Mark E Obrien, MD received $16.02 in general payments during 2025 across 1 reported records.

Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$16.02

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$16.02	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$16.02	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
JARDIANCE Normalized: jardiance	Drug	Boehringer Ingelheim Pharmaceuticals, Inc.	$16.02	1	2025
Source payment records 2025-01-16 · Boehringer Ingelheim Pharmaceuticals, Inc. · $16.02 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
JARDIANCE jardiance	2025	Jardiance	2024	36	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583	Jardiance · 2024 Exact normalized brand match · 1 Part D row	36	15

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	745	182
Atorvastatin Calcium	Atorvastatin Calcium	616	163
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	491	90
Omeprazole	Omeprazole	404	95
Lisinopril	Lisinopril	383	96
Hydrochlorothiazide	Hydrochlorothiazide	356	98
Metformin Hcl	Metformin Hcl	290	77
Gabapentin	Gabapentin	287	62
Losartan Potassium	Losartan Potassium	284	72
Albuterol Sulfate Hfa	Albuterol Sulfate	253	72
Furosemide	Furosemide	226	56
Levothyroxine Sodium	Levothyroxine Sodium	226	45
Tamsulosin Hcl	Tamsulosin Hcl	192	43
Glipizide	Glipizide	146	30
Metoprolol Tartrate	Metoprolol Tartrate	140	39
Ibuprofen	Ibuprofen	130	43
Pantoprazole Sodium	Pantoprazole Sodium	130	35
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	127	34
Sertraline Hcl	Sertraline Hcl	124	27
Atenolol	Atenolol	104	33
Metoprolol Succinate	Metoprolol Succinate	104	26
Tizanidine Hcl	Tizanidine Hcl	103	26
Allopurinol	Allopurinol	98	24
Clonidine Hcl	Clonidine Hcl	97	23
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	94	20
Potassium Chloride	Potassium Chloride	90	23
Alprazolam	Alprazolam	87	14
Carvedilol	Carvedilol	86	26
Quetiapine Fumarate	Quetiapine Fumarate	84	13
Eliquis	Apixaban	81	20
Simvastatin	Simvastatin	80	19
Meloxicam	Meloxicam	78	23
Trazodone Hcl	Trazodone Hcl	76	21
Citalopram Hbr	Citalopram Hydrobromide	62	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	62	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	61	16
Terazosin Hcl	Terazosin Hcl	61	17
Clopidogrel	Clopidogrel Bisulfate	59	20
Tramadol Hcl	Tramadol Hcl	56	18
Mirtazapine	Mirtazapine	51	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	50	13
Montelukast Sodium	Montelukast Sodium	50	12
Chlorthalidone	Chlorthalidone	49	14
Levetiracetam	Levetiracetam	49	12
Hydralazine Hcl	Hydralazine Hcl	45	14
Isosorbide Mononitrate Er	Isosorbide Mononitrate	45	11
Ventolin Hfa	Albuterol Sulfate	45	14
Duloxetine Hcl	Duloxetine Hcl	42	11
Pregabalin	Pregabalin	40	suppressed
Clonazepam	Clonazepam	39	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	38	suppressed
Pravastatin Sodium	Pravastatin Sodium	38	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	38	20
Atrovent Hfa	Ipratropium Bromide	36	suppressed
Diazepam	Diazepam	36	suppressed
Jardiance	Empagliflozin	36	15
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	35	suppressed
Fluticasone Propionate	Fluticasone Propionate	35	15
Nifedipine Er	Nifedipine	35	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	34	suppressed
Diclofenac Sodium	Diclofenac Sodium	33	11
Lantus	Insulin Glargine,hum.Rec.Anlog	33	suppressed
Prednisone	Prednisone	33	19
Meclizine Hcl	Meclizine Hcl	32	suppressed
Famotidine	Famotidine	31	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	31	suppressed
Warfarin Sodium	Warfarin Sodium	31	suppressed
Farxiga	Dapagliflozin Propanediol	30	suppressed
Trulicity	Dulaglutide	30	suppressed
Januvia	Sitagliptin Phosphate	29	suppressed
Alendronate Sodium	Alendronate Sodium	28	suppressed
Colchicine	Colchicine	28	suppressed
Olanzapine	Olanzapine	28	suppressed
Spironolactone	Spironolactone	28	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	28	suppressed
Ibu	Ibuprofen	27	suppressed
Bupropion Xl	Bupropion Hcl	23	suppressed
Cephalexin	Cephalexin	23	19
Naproxen	Naproxen	23	11
Symbicort	Budesonide/Formoterol Fumarate	23	suppressed
Ozempic	Semaglutide	22	suppressed
Risperidone	Risperidone	22	suppressed
Xarelto	Rivaroxaban	22	suppressed
Glimepiride	Glimepiride	21	suppressed
Baclofen	Baclofen	20	suppressed
Divalproex Sodium Er	Divalproex Sodium	20	suppressed
Latanoprost	Latanoprost	20	suppressed
Digoxin	Digoxin	19	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	19	17
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Torsemide	Torsemide	19	suppressed
Amoxicillin	Amoxicillin	18	16
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	18	suppressed
Azithromycin	Azithromycin	17	16
Dropsafe Prep Pads	Alcohol Antiseptic Pads	16	suppressed
Fentanyl	Fentanyl	16	suppressed
Lovastatin	Lovastatin	16	suppressed
Novolog Flexpen	Insulin Aspart	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	16	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	15	suppressed
Hydrocortisone	Hydrocortisone	15	suppressed
Nitroglycerin	Nitroglycerin	15	suppressed
Glipizide Er	Glipizide	14	suppressed
Levemir	Insulin Detemir	14	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	14	suppressed
Phenobarbital	Phenobarbital	14	suppressed
Breo Ellipta	Fluticasone/Vilanterol	13	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Trifluoperazine Hcl	Trifluoperazine Hcl	13	suppressed
Valsartan	Valsartan	13	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	13	suppressed
Dilt-Xr	Diltiazem Hcl	12	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Celecoxib	Celecoxib	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	11	suppressed
Glyburide	Glyburide	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Topiramate	Topiramate	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$16.02 · 1 records	Boehringer Ingelheim Pharmaceuticals, Inc.	JARDIANCE	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Jardiance play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error